SEHK:2616Biotechs
A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Encouraging CS2009 Trial Results And Wider Losses
CStone Pharmaceuticals (SEHK:2616) has drawn fresh attention after reporting detailed Phase I/II data for CS2009, its trispecific antibody, alongside full year 2025 results that show CNY 269.58 million in sales and a CNY 437 million net loss.
See our latest analysis for CStone Pharmaceuticals.
The encouraging CS2009 data appears to be feeding into a strong shift in sentiment, with a 1 day share price return of 5.04% and a 7 day share price return of 40.68% at HK$8.75. Momentum has been...